Trials / Completed
CompletedNCT00211497
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 255 (planned)
- Sponsor
- BioWest Therapeutics Inc · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBI 226 Acne Solutions |
Timeline
- Start date
- 2003-01-01
- Completion
- 2003-09-01
- First posted
- 2005-09-21
- Last updated
- 2005-09-21
Source: ClinicalTrials.gov record NCT00211497. Inclusion in this directory is not an endorsement.